Evidence map›Paper›PMID 35904681›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2022

Sickle cell bone disease and response to intravenous bisphosphonates in children.

C Grimbly, P Diaz Escagedo, J L Jaremko, A Bruce, N Alos, M E Robinson, V N Konji, M Page, M Scharke, E Simpson and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Alendronate preserves bone mineral density in adults with sickle cell disease and osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Article
  8. Should we use bisphosphonates to treat bone complications in sickle cell disease?Hematology. American Society of Hematology. Education Program · 2024
    Article
  9. Review
  10. Article
  11. A bone to pick-cellular and molecular mechanisms of bone pain in sickle cell disease.Frontiers in pain research (Lausanne, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

C GrimblyDepartment of Pediatrics, University of Alberta, 4-584 Edmonton Clinic Health Academy, 11405 - 87 Ave, Edmonton, AB, T6G 2R7, Canada. cgrimbly@ualberta.ca.ORCID http://orcid.org/0000-0002-9302-7741
P Diaz EscagedoDepartment of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, Université de Montreal, Montreal, QC, Canada.ORCID http://orcid.org/0000-0001-6469-3510
J L JaremkoDepartment of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada.
A BruceDepartment of Pediatrics, University of Alberta, 4-584 Edmonton Clinic Health Academy, 11405 - 87 Ave, Edmonton, AB, T6G 2R7, Canada.ORCID http://orcid.org/0000-0001-5754-017X
N AlosDepartment of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, Université de Montreal, Montreal, QC, Canada.ORCID http://orcid.org/0000-0003-1258-7665
M E RobinsonDepartment of Pediatrics, University of Ottawa, Ottawa, ON, Canada.ORCID http://orcid.org/0000-0002-2539-227X
V N KonjiThe Ottawa Pediatric Bone Health Research Group, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
M PageDepartment of Pediatrics, University of Ottawa, Ottawa, ON, Canada.
M ScharkeThe Ottawa Pediatric Bone Health Research Group, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
E SimpsonDepartment of Pediatrics, University of Ottawa, Ottawa, ON, Canada.ORCID http://orcid.org/0000-0002-6052-5904
Y D PastoreDepartment of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, Université de Montreal, Montreal, QC, Canada.
R GirgisDepartment of Pediatrics, University of Alberta, 4-584 Edmonton Clinic Health Academy, 11405 - 87 Ave, Edmonton, AB, T6G 2R7, Canada.
R T AlexanderDepartment of Pediatrics, University of Alberta, 4-584 Edmonton Clinic Health Academy, 11405 - 87 Ave, Edmonton, AB, T6G 2R7, Canada.ORCID http://orcid.org/0000-0001-7396-7894
L M WardDepartment of Pediatrics, University of Ottawa, Ottawa, ON, Canada.
University of Ottawa · CACentre Hospitalier Universitaire Sainte-Justine · CAUniversity of Alberta · CAChildren's Hospital of Eastern Ontario · CAUniversity of Alberta Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Children with sickle cell disease (SCD) have the potential for extensive and early-onset bone morbidity. This study reports on the diversity of bone morbidity seen in children with SCD followed at three tertiary centers. IV bisphosphonates were effective for bone pain analgesia and did not trigger sickle cell complications.

introductionTo evaluate bone morbidity and the response to intravenous (IV) bisphosphonate therapy in children with SCD.

methodsWe conducted a retrospective review of patient records from 2003 to 2019 at three Canadian pediatric tertiary care centers. Radiographs, magnetic resonance images, and computed tomography scans were reviewed for the presence of avascular necrosis (AVN), bone infarcts, and myositis. IV bisphosphonates were offered for bone pain management. Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA).

resultsForty-six children (20 girls, 43%) had bone morbidity at a mean age of 11.8 years (SD 3.9) including AVN of the femoral (17/46, 37%) and humeral (8/46, 17%) heads, H-shaped vertebral body deformities due to endplate infarcts (35/46, 76%), and non-vertebral body skeletal infarcts (15/46, 32%). Five children (5/26, 19%) had myositis overlying areas of AVN or bone infarcts visualized on magnetic resonance imaging. Twenty-three children (8/23 girls) received IV bisphosphonate therapy. They all reported significant or complete resolution of bone pain. There were no reports of sickle cell hemolytic crises, pain crises, or stroke attributed to IV bisphosphonate therapy.

conclusionChildren with SCD have the potential for extensive and early-onset bone morbidity. In this series, IV bisphosphonates were effective for bone pain analgesia and did not trigger sickle cell complications.

Indexed as

Anemia, Sickle CellMyositisOsteonecrosisCanadaChildDiphosphonatesFemaleHumansInfarctionPainDiphosphonates(4–6): childrenAvascular necrosisBisphosphonateBone infarctsMyositisSickle cell disease.

Identifiers

PMID35904681
PMCPMC9568449
OpenAlexW4288535363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.